Since their clinical introduction in the 1930s, antibiotics have greatly influenced life on Earth.[1] Over the past 80 years, antibiotics have enabled tremendous advances in modern medicine and revolutionized agricultural and industrial practice. Antibiosis is now deeply integrated into a modern way of life, with the widespread use of antibiotics and biocides resembling the ubiquity of bacteria themselves. Ironically, antibiotics have facilitated the very developments in travel and trade through economic globalization that have contributed to the rapid dissemination of antimicrobial resistance (AMR). Warnings of resistance preceded the clinical use of antibiotics,[201] and since then the introduction of every antimicrobial product has been closely followed by the emergence of resistance against it. Four decades of exorbitant antibiotic use has applied unprecedented selective pressure towards high-level AMR and multiple-drug resistance (MDR), rendering entire classes of antibiotics redundant and threatening to bring about the end of the 'antibiotic era'.[1,2] The traditional response to emerging resistance has been the timely introduction of a new class of compounds, temporarily assuaging the concerns of modern medicine. However, over the last two decades, there has been a significant retraction of investment towards antimicrobial R&D by the major pharmaceutical companies. This has resulted in a substantial decline in novel antimicrobials, and a production rate currently failing to keep pace with the coinciding escalation in global resistance.[3]